Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.
However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Some of the limitations of clinical trial results in terms of generalizability to the larger population include:
Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.
Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.
Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.
Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.
However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.
Share this story...
Real World Evidence (RWE) 101 – Is ICH GCP Applicable to Non-Interventional Studies?
RWE 101 - Is ICH GCP Applicable to Non-Interventional Studies? No, the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines are not applicable to non-interventional studies [...]
Real World Evidence (RWE) 101 – Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence
RWE 101 - Real World Evidence (RWE) 101 - Ethical Principles and Safeguards for Medical AI in the Context of Real World Evidence Medical AI applications hold [...]
Real World Evidence (RWE) 101 – The Declaration of Helsinki
RWE 101 - The Declaration of Helsinki The Declaration of Helsinki is a set of ethical principles that govern the conduct of medical research involving human subjects. [...]
Real World Evidence (RWE) 101 – Ethical Foundation of RWE Research
RWE 101 - Real World Evidence (RWE) 101 - Ethical Foundation of RWE Research Real-world evidence (RWE) research, which is the study of data from real-world settings, is [...]
Real World Evidence (RWE) 101 – The Impact of GDPR on RWE Research
RWE 101 - Real World Evidence (RWE) 101 - The Impact of GDPR on RWE Research The General Data Protection Regulation (GDPR) is a regulation in EU [...]
Real World Evidence (RWE) 101 – De-Identification versus Pseudo-Anonymisation
RWE 101 - Real World Evidence (RWE) 101 - De-Identification versus Pseudo-Anonymisation De-identification and pseudo-anonymization are two commonly used techniques for protecting personal information in real world [...]







